J&J's quarterly report details $5.5 billion talc ovarian deal and a $9 billion total talc reserve

Johnson & Johnson's quarterly report spells out the cost of its plan to settle the ovarian cancer talc lawsuits: a $5.5 billion charge in the third quarter, and a total talc reserve that now stands at about $9.0 billion.

The company recorded the $5.5 billion accrual for the proposed resolution of the talc ovarian litigation in its fiscal third quarter, according to its 10-Q filed Wednesday. That charge is the main reason diluted EPS fell to 9 cents from $2.12 a year earlier, results the company first reported on Oct. 13.

The settlement terms

J&J said it announced the plan in July, after favorable rulings in the federal multi-district litigation in New Jersey and the plaintiffs' withdrawal of their causation experts in the first bellwether cases. It reached an agreement with plaintiff firms leading the federal and related state court cases.

The deal is conditioned on, among other things, the express participation of at least 95% of the remaining claims, according to the 10-Q. It does not cover the mesothelioma cases, which remain ongoing, and the company also faces talc litigation in Canada.

The total talc reserve of about $9.0 billion, measured at present value, includes the ovarian settlement, other executed settlements, defense costs and other costs. About half is recorded as a current liability.

Other items in the filing

The quarter also included $1.0 billion of acquired in-process research and development expense tied to the acquisition of Firefly Bio, the company said in its quarterly report.

As of Sept. 27, J&J held about $17.2 billion in cash and marketable securities against roughly $44.6 billion of debt, for net debt of $27.4 billion, compared with $27.2 billion a year earlier. The company listed the talc balance, $3.2 billion of bonds coming due, about $2.6 billion for an option to acquire Sail Biomedicines and about $0.9 billion in remaining opioid settlement payments among the obligations it expects to fund.

By the numbers

• Q3 talc ovarian accrual: $5.5 billion
• Total talc reserve: about $9.0 billion
• Required claimant participation: at least 95%
• Firefly Bio in-process R&D charge: $1.0 billion
• Net debt: $27.4 billion

Sources

1. Johnson & Johnson, Form 10-Q for the fiscal quarter ended Sept. 27, 2026, filed Oct. 21, 2026, accession 0000200406-26-000197

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.